COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics

COMPASS Pathways PLC ADR (CMPS): $8.25

0.11 (-1.32%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

CMPS Price/Volume Stats

Current price $8.25 52-week high $12.75
Prev. close $8.36 52-week low $5.01
Day low $8.21 Volume 355,120
Day high $8.65 Avg. volume 681,485
50-day MA $9.89 Dividend yield N/A
200-day MA $8.48 Market Cap 511.03M

CMPS Stock Price Chart Interactive Chart >


COMPASS Pathways PLC ADR (CMPS) Company Bio


COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.


CMPS Latest News Stream


Event/Time News Detail
Loading, please wait...

CMPS Latest Social Stream


Loading social stream, please wait...

View Full CMPS Social Stream

Latest CMPS News From Around the Web

Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditionsLONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that an initial data readout showed that investigational COMP360 psilocybin treatment was well-tolerated in a phase 2 clinical trial of people living with post-tr

Yahoo | December 19, 2023

25 Best Online Psychology Degree Programs Heading Into 2024

In this article, we will be looking at the 25 best online psychology degree programs heading into 2024. If you want to skip our detailed analysis, you can go directly to the 5 Best Online Psychology Degree Programs Heading Into 2024. Global Mental Health Industry: An Overview According to a report by IMARC, the global mental health […]

Yahoo | December 13, 2023

Compass Pathways appoints Teri Loxam as Chief Financial Officer

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company’s New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO. Teri brings to Compass deep and

Yahoo | December 7, 2023

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depressionLONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper inJAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder (bipolar II). Res

Yahoo | December 6, 2023

Investing in Mental Health: 3 Stocks in the Wellness Space

Mental health stocks can be a great addition to your portfolio as its importance becomes increasingly recognized.

Matthew Farley on InvestorPlace | December 5, 2023

Read More 'CMPS' Stories Here

CMPS Price Returns

1-mo -8.13%
3-mo -12.79%
6-mo 51.10%
1-year -1.08%
3-year -76.63%
5-year N/A
YTD -5.71%
2023 8.97%
2022 -63.67%
2021 -53.61%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!